Thinking “outside the germinal center”: Re-educating T cells to combat follicular lymphoma

IF 6.9 2区 医学 Q1 HEMATOLOGY
Swetha Kambhampati , Geoffrey Shouse , Alexey V. Danilov
{"title":"Thinking “outside the germinal center”: Re-educating T cells to combat follicular lymphoma","authors":"Swetha Kambhampati ,&nbsp;Geoffrey Shouse ,&nbsp;Alexey V. Danilov","doi":"10.1016/j.blre.2023.101099","DOIUrl":null,"url":null,"abstract":"<div><p><span><span>There have been significant advancements in the management of follicular lymphoma<span><span> (FL), the most common indolent lymphoma. These include immunomodulatory agents such as lenalidomide, </span>epigenetic<span> modifiers (tazemetostat), and phosphoinotiside-3 kinase inhibitors<span> (copanlisib). The focus of this review is T cell-engager therapies, namely </span></span></span></span>chimeric antigen receptor<span> (CAR) T-cell therapy and bispecific antibodies, have recently transformed the treatment landscape of FL. Two CAR </span></span>T cell<span><span><span> products, axicabtagene ciloleucel<span> (axi-cel) and tisagenlecleucel (tisa-cel), and one bispecific antibody, </span></span>mosunetuzumab, recently received FDA approvals in FL. Several other new immune effector </span>drugs are being evaluated and will expand the treatment armamentarium. This review focuses on CAR T-cell and bispecific antibody therapies, details their safety and efficacy and considers their evolving role in the current treatment landscape of FL.</span></p></div>","PeriodicalId":56139,"journal":{"name":"Blood Reviews","volume":null,"pages":null},"PeriodicalIF":6.9000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood Reviews","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0268960X23000607","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

There have been significant advancements in the management of follicular lymphoma (FL), the most common indolent lymphoma. These include immunomodulatory agents such as lenalidomide, epigenetic modifiers (tazemetostat), and phosphoinotiside-3 kinase inhibitors (copanlisib). The focus of this review is T cell-engager therapies, namely chimeric antigen receptor (CAR) T-cell therapy and bispecific antibodies, have recently transformed the treatment landscape of FL. Two CAR T cell products, axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel), and one bispecific antibody, mosunetuzumab, recently received FDA approvals in FL. Several other new immune effector drugs are being evaluated and will expand the treatment armamentarium. This review focuses on CAR T-cell and bispecific antibody therapies, details their safety and efficacy and considers their evolving role in the current treatment landscape of FL.

思考“生发中心外”:重新培养T细胞对抗滤泡性淋巴瘤
滤泡性淋巴瘤(FL)是最常见的惰性淋巴瘤,其治疗已取得重大进展。其中包括免疫调节剂,如来那度胺、表观遗传学修饰剂(他唑美司他)和磷酸肌醇3激酶抑制剂(copanlisib)。这篇综述的重点是T细胞接合剂疗法,即嵌合抗原受体(CAR)T细胞疗法和双特异性抗体,最近改变了FL的治疗格局。两种CAR T细胞产品,axcabtagene cilloucel(axi-cel)和tisagenleucel(tisa-cel),以及一种双特异性的抗体mosunetuzumab,最近在FL获得了美国食品药品监督管理局的批准。其他几种新的免疫效应药物正在评估中,并将扩大治疗范围。这篇综述的重点是CAR T细胞和双特异性抗体疗法,详细介绍了它们的安全性和有效性,并考虑了它们在当前FL治疗前景中不断发展的作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Blood Reviews
Blood Reviews 医学-血液学
CiteScore
13.80
自引率
1.40%
发文量
78
期刊介绍: Blood Reviews, a highly regarded international journal, serves as a vital information hub, offering comprehensive evaluations of clinical practices and research insights from esteemed experts. Specially commissioned, peer-reviewed articles authored by leading researchers and practitioners ensure extensive global coverage across all sub-specialties of hematology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信